Cogent Biosciences, Inc. COGT Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cogent Biosciences, Inc.'s accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cogent Biosciences, Inc.'s accrued expenses and other liabilities?
- Cogent Biosciences, Inc. (COGT) reported accrued expenses and other liabilities of -$10.2M in Q1 2026.
- How has Cogent Biosciences, Inc.'s accrued expenses and other liabilities changed year-over-year?
- Cogent Biosciences, Inc.'s accrued expenses and other liabilities decreased by 17.8% year-over-year, from -$8.66M to -$10.2M.
- What is the long-term trend for Cogent Biosciences, Inc.'s accrued expenses and other liabilities?
- Over 4 years (2021 to 2025), Cogent Biosciences, Inc.'s accrued expenses and other liabilities has grown at a 32.8% compound annual growth rate (CAGR), from $3.43M to $10.69M.